EDUCATION CENTER

What are peptides?

Peptides are short chains of amino acids—the same building blocks that make proteins. Many act as signaling molecules: they bind receptors, then clear relatively quickly compared with long-acting steroids or some small-molecule drugs.

Your body already makes countless peptides (for example, insulin is a peptide hormone). Therapeutic peptides used in clinic are typically synthetic versions or analogs designed to mimic or modify a natural signal. That is different from protein powders, collagen supplements, or “research chemical” vials sold online without a prescription.

In medical education, “peptide” is a chemistry category—not a guarantee of safety, FDA approval, or sports-legal status. Each compound has its own evidence, risks, and regulatory path.

What is peptide therapy?

Peptide therapy means using clinician-directed peptide medicines as part of a supervised plan—after intake, screening, and a written protocol—not buying unlabeled research products. A provider matches the compound (or decides none is appropriate) and pairs it with sleep, protein, and rehab when recovery is the goal.

Read the full “what is peptide therapy” guide →

Which peptides are used for recovery?

In clinic conversations, “recovery” peptides often include compounds discussed for soft-tissue comfort and repair context—such as BPC-157 and TB-500 (thymosin beta-4–related fragments)—and sometimes GH-axis peptides when recovery goals overlap with sleep, body composition, or healing capacity.

Which peptide is actually used depends on your diagnosis, regulatory availability, anti-doping status if you are a tested athlete, and whether rehab, imaging, or surgery should come first. A peptide does not replace diagnosing a tear, infection, or training-error injury.

Expect a recovery plan to include progressive loading, protein intake, and sleep. Medication or peptide support, when used, is an adjunct—not a license to train through sharp or worsening pain.

What peptides are being studied for muscle recovery?

Most published work on peptides marketed for muscle or soft-tissue recovery is preclinical: animal injury models and cell studies. BPC-157 has extensive rodent and cell literature on tendon, muscle, and vascular signaling; TB-500 / thymosin-β4 biology has been studied for cell migration and wound-related pathways.

Human evidence is thinner. Small clinic series and early or ongoing trials are not the same as large randomized outcomes trials. When you read “studied for muscle recovery,” check whether the paper is a rat model, a cell dish, a retrospective clinic note, or a registered human trial with published results.

Growth-hormone–axis peptides (for example GHRH analogs or GH secretagogues) are sometimes discussed when clinicians want GH/IGF-1 pathway support; that is a different mechanism conversation from local tissue-repair peptides and still requires medical screening.

What is BPC-157?

BPC-157 (Body Protection Compound-157) is a synthetic 15–amino-acid peptide modeled on a fragment related to a protective protein in gastric juice. It is not an FDA-approved drug and is not a dietary supplement with an established legal supplement identity.

Preclinical research has explored tissue protection and repair—especially gut lining, tendon, ligament, muscle, and blood-vessel signaling. Human controlled outcome data remain limited. Athletes under WADA rules should know BPC-157 is listed among non-approved substances prohibited at all times.

Whether BPC-157 is appropriate or even available for your situation is a clinician and pharmacy-regulatory question. Read the dedicated BPC-157 education pages for deeper FDA, evidence, and safety detail.

What is CJC-1295?

CJC-1295 is a synthetic analog of growth hormone–releasing hormone (GHRH). In clinical research, long-acting CJC-1295 formulations have been studied for prolonged stimulation of GH and IGF-I secretion in healthy adults.

Clinicians may discuss CJC-1295 when the therapeutic intent involves GH-axis signaling—often alongside careful lab monitoring—not as a casual “anti-aging shot.” It is different from injecting growth hormone itself, and it is different from local recovery peptides like BPC-157.

Product form, dosing schedule, and whether a DAC (drug affinity complex) variant is involved change duration of action. Do not copy a social-media protocol. A Vita Bella provider decides if a GHRH analog belongs in your plan and how it will be monitored.

What is ipamorelin?

Ipamorelin is a selective growth hormone secretagogue (ghrelin-receptor pathway) studied for stimulating GH release. Pharmacokinetic–pharmacodynamic work in human volunteers has characterized how it drives GH responses.

In practice, ipamorelin is sometimes discussed alone or paired with a GHRH analog such as CJC-1295 when a clinician wants complementary GH-axis signaling. Pairing is a designed protocol—not something to invent from a chart online.

Like other GH-axis agents, candidacy depends on goals, contraindications, glucose and IGF-1 context, and follow-up. It is not a substitute for sleep, protein, or progressive training when body composition is the goal.

Are peptides safe?

Safety is compound-specific and situation-specific. Approved peptide drugs have labeled risks and monitoring. Compounded or investigational peptides can have less mature human safety data, quality-control variability, and regulatory limits on when they may be prepared.

General risks can include injection-site reactions, immune responses, dosing errors, contamination from unregulated products, and unexpected interactions. GH-axis peptides can affect glucose and IGF-1 pathways. Soft-tissue “recovery” peptides may still carry anti-doping consequences for tested athletes even when marketed as wellness.

“Natural because it is a peptide” is not a safety argument. The safer path is clinician screening, a known pharmacy source when therapy is used, and scheduled follow-up—not anonymous research vials.

Which peptides are FDA approved?

Some peptides are FDA-approved medicines with labeling—insulin is the classic example; other approved peptide hormones and analogs exist for specific endocrine and metabolic indications (for example, certain growth hormone and related therapies under labeled use). Approval is always for a defined product and indication, not for “peptides” as a category.

Many compounds discussed in wellness or recovery marketing—including BPC-157—are not FDA-approved for any human indication. Compounding rules under the FD&C Act are separate from approval: a bulk substance is not automatically legal to compound just because it is popular.

Your Vita Bella clinician will distinguish approved products, compounded options that are currently permissible, and compounds that should not be used. Do not assume a clinic advertisement equals FDA approval.

What should I know before considering peptide therapy?

Start with a clear goal and a medical evaluation: history, medications, allergies, prior surgeries or injuries, fertility or pregnancy plans, and relevant labs. Bring any anti-doping or workplace testing requirements up front.

Ask what the peptide is expected to do, what evidence supports that use, alternatives (rehab, nutrition, sleep, approved medicines), monitoring plan, cost drivers, and what happens if you stop. Confirm the source is a clinician-directed pharmacy pathway—not a research-chemical marketplace.

If peptide therapy is not appropriate, that is a successful consult. Vita Bella’s job is to match tools to your situation—or to say no when the safer plan is something else.

FAQs

References

1. 1. Lau JL, Dunn MK. Therapeutic peptides: Historical perspectives, current development trends, and future directions. Bioorg Med Chem. 2018;26(10):2700-2707.

2. 2. U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers.

3. 3. U.S. Food and Drug Administration. Bulk Drug Substances Used in Compounding Under Section 503A of the FD&C Act.

4. 4. Teichman SL, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799-805.

5. 5. Gobburu JV, et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone secretagogue, in human volunteers. Pharm Res. 1999;16(9):1412-1416.

6. 6. World Anti-Doping Agency. WADA’s 2022 Prohibited List now in force (BPC-157 named under S0 Non-approved Substances).

7. 7. Gwyer D, Wragg NM, Wilson SL. Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing. Cell Tissue Res. 2019.

Related guides